Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Christopher J. Hoimes, DO, an assistant professor in the Department of Medicine Division of Hematology and Oncology at the School of Medicine and a member of the Genitourinary Malignancies Program at Case Comprehensive Cancer Center, Case Western Reserve University, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Patients with urothelial carcinoma who are cisplatin-ineligible represent a population of unmet need. At this time, cisplatin-combination chemotherapy is the recommended treatment, but many patients are not eligible for this therapy. The therapeutic options for these patients are limited, as well, notes Hoimes.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More